Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nelarabine with Modified BFM Chemotherapy for T-Cell ALL
NCT00016302Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Apr 2001
- Primary completion
- Jul 2007
- Modality
- Prodrugs/Conditional Activator Small Molecules, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label trial of nelarabine in t-cell acute lymphoblastic leukemia (T-ALL) (6 arms), sponsored by National Cancer Institute. Primary endpoint: Feasibility of the addition of nelarabine to modified multiagent BFM chemotherapy up to 6 years. Started Apr 2001; status: completed.
02
Drugs
nelarabine
03
Conditions
t-cell acute lymphoblastic leukemia (T-ALL)
Beyond the preview
Go deeper on NCT00016302.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00016302.